SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-239876
Filing Date
2021-08-09
Accepted
2021-08-09 07:37:56
Documents
13
Period of Report
2021-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d182516d8k.htm   iXBRL 8-K 26358
2 EX-99.1 d182516dex991.htm EX-99.1 95719
  Complete submission text file 0001193125-21-239876.txt   257204

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA itci-20210809.xsd EX-101.SCH 2932
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20210809_lab.xml EX-101.LAB 17372
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20210809_pre.xml EX-101.PRE 10979
6 EXTRACTED XBRL INSTANCE DOCUMENT d182516d8k_htm.xml XML 3214
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 211154647
SIC: 2834 Pharmaceutical Preparations